Arrowhead Pharmaceuticals (ARWR) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to -$922.4 million.
- Arrowhead Pharmaceuticals' Enterprise Value fell 6787.14% to -$922.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$922.4 million, marking a year-over-year decrease of 6787.14%. This contributed to the annual value of -$882.0 million for FY2025, which is 3060.08% down from last year.
- Per Arrowhead Pharmaceuticals' latest filing, its Enterprise Value stood at -$922.4 million for Q4 2025, which was down 6787.14% from -$882.0 million recorded in Q3 2025.
- Arrowhead Pharmaceuticals' 5-year Enterprise Value high stood at -$165.3 million for Q4 2021, and its period low was -$1.1 billion during Q1 2025.
- Over the past 5 years, Arrowhead Pharmaceuticals' median Enterprise Value value was -$457.5 million (recorded in 2021), while the average stood at -$520.1 million.
- In the last 5 years, Arrowhead Pharmaceuticals' Enterprise Value plummeted by 19195.27% in 2022 and then surged by 5709.82% in 2023.
- Over the past 5 years, Arrowhead Pharmaceuticals' Enterprise Value (Quarter) stood at -$165.3 million in 2021, then crashed by 191.95% to -$482.5 million in 2022, then skyrocketed by 57.1% to -$207.0 million in 2023, then crashed by 165.42% to -$549.4 million in 2024, then crashed by 67.87% to -$922.4 million in 2025.
- Its Enterprise Value stands at -$922.4 million for Q4 2025, versus -$882.0 million for Q3 2025 and -$902.9 million for Q2 2025.